CODA Biotherapeutics' Chemogenetic Gene Therapy Platform Can Control Focal Seizures in vivo
/PRNewswire/ -- CODA Biotherapeutics, Inc. ("CODA"), today announced the presentation of preclinical data suggesting that the Company's chemogenetic gene...
Source: prnewswire.com